June 8, 2022 — Take that, Omicron. Outcomes of a trial a mix COVID-19 vaccine booster reveals a “sturdy antibody response” towards the Omicron variant, vaccine producer Moderna introduced Wednesday.
The neutralizing antibody response was eight occasions better at 1 month following a 50-mcg dose with the booster containing each the unique mRNA-1273 vaccine and a brand new vaccine in improvement that particularly targets the Omicron variant.
The bivalent vaccine, mRNA-1273.214, was in comparison with a 50-mcg dose of the unique vaccine alone in 473 seronegative individuals within the Part 2/3 trial.
These outcomes provide promise of better safety towards Omicron following earlier stories that confirmed that current COVID-19 vaccines weren’t as efficient towards the Omicron variant.
Security and tolerability of the brand new vaccine was per a previous booster dose of the unique vaccine, the corporate reported.
Moderna additionally has a bivalent vaccine booster in improvement that features the unique vaccine and a vaccine particular to the Beta variant of SARS-CoV-2, the virus that causes COVID-19.
Moderna plans to file this new information with the FDA as a part of its utility requesting authorization.
“We anticipate extra sturdy safety towards variants of concern with mRNA-1273.214, making it our lead candidate for a Fall 2022 booster,” Stephane Bancel, chief government officer at Moderna, stated in an organization information launch. “We’re submitting our preliminary information and evaluation to regulators with the hope that the Omicron-containing bivalent booster shall be out there within the late summer time.”
